Cipla acquires novel anti-infective Elores from Venus Remedies

18 Oct 2019 Evaluate

Cipla has acquired a novel and patented anti-infective product, Elores, from Venus Remedies (VRL) for the Indian market to further strengthen its presence in the branded Indian critical care space and as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR).

Elores is a novel combination of Ceftriaxone (a third generation beta-lactam cephalosporin), Sulbactam (a beta-lactamase inhibitor) and Disodium EDTA (an Antibiotic Resistance Breaker) indicated for the treatment of life threatening infections caused by gram-negative bacteria. It preserves the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs).

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1351.85 4.20 (0.31%)
02-Mar-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1752.70
Dr. Reddys Lab 1294.65
Cipla 1351.85
Zydus Lifesciences 906.85
Lupin 2313.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×